We tested if rates of brain atrophy accelerate in individuals with amnestic mild cognitive impairment (aMCI) as they progress to typical late onset Alzheimer disease (AD). We included comparisons to subjects with aMCI who did not progress (labeled aMCI-S) and also to cognitively normal elderly subjects (CN).
Alzheimer disease (AD) is characterized by progressive deterioration of the neuropil 1-3 which is detected macroscopically as cerebral atrophy on MRI. Progressive atrophy both precedes and parallels the observed clinical decline in affected individuals and brain shrinkage over time can be detected by serial MRI studies. [4] [5] [6] [7] Cross-sectional MRI studies of individuals spanning various age ranges have been performed to evaluate age effects on brain morphometry. However, this approach suffers from cohort effects and other biases. Serial measurements acquired in the same individuals are needed to assess atrophy rates. The limited number of longitudinal MRI studies published in normal aging, mild cognitive impairment (MCI), or AD typically employ two scans acquired at different time points from which a rate of change is calculated. These studies have provided estimates of the rates of morphometric change over time and demonstrated increased rates among AD and MCI relative to similarly aged cognitively normal elderly subjects, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and increased rates in subjects with MCI who progress to AD relative to subjects with MCI who do not. 11, 12 However, by sampling two time points per subject, characterization of longitudinal morphometric trajectory on a per subject basis is linear by default. In order to more directly assess a change in rate with time in individual subjects-i.e., acceleration or decelerationthree or more time points must be sampled in each subject. To our knowledge, this phenomenon has been studied only in young individuals with familial AD. 20, 21 The purpose of our study was to test if the rates of whole brain shrinkage and ventricular expansion accelerate in elderly subjects with amnestic mild cognitive impairment (aMCI). We were particularly interested to see if rates of atrophy accelerate as individuals with aMCI progress to AD. MCI progressors were contrasted with a group of subjects with aMCI who did not progress to dementia. Comparison to a group of cognitively normal elderly subjects was included for reference purposes.
METHODS Subjects. All subjects were identified from the Mayo AD Research Center or AD Patient Registry. 22 These are longitudinal studies of aging and dementia which include serial clinical and cognitive assessments. At baseline all subjects met criteria for cognitively normal (CN) or aMCI. Categorization into diagnostic groups was made on a clinical basis at consensus conferences involving neurologists, neuropsychologists, a neuropsychiatrist, and study coordinators. Criteria for the diagnosis of CN were 1) no active neurologic or psychiatric disorders; 2) some subjects may have had ongoing medical problems yet the illnesses or their treatments did not interfere with cognitive function; 3) normal neurologic examination; 4) independently functioning community dwellers. Potential aMCI subjects were identified as having possible memory impairment during routine outpatient general medical visits; i.e., these subjects were not recruited from memory clinic referrals. Criteria for the diagnosis of aMCI were those of Petersen et al 23 : 1) memory impairment documented by the patient and collateral source; 2) relatively normal general cognition; 3) normal activities of daily living; 4) not demented (Diagnostic and Statistical Manual of Mental Disorders-3-R); 5) memory impaired for age and education. In general, the aMCI determination is made when the memory measures fall Ϫ1.0 to Ϫ1.5 SD below the means for age and education appropriate individuals in our community. 24 The memory measures used include the Wechsler Memory Scale Revised Logical Memory and Visual Reproductions subtests, 25 the Auditory Verbal Learning Test (AVLT), 26 and the Free and Cued Selective Reminding Test. 27 The most salient measures are those involving delayed recall. For other cognitive domains, subtests from the Wechsler Adult Intelligence Scale Revised were used including Digit Span, Digit Symbol Substitution, Block Design, Picture Completion, Object Assembly, as well as other measures including the Boston Naming Test, 28 category fluency, and Trailmaking A and B. Measures of global function were also used including the Clinical Dementia Rating (CDR), 29 Mini-Mental State Examination (MMSE), 30 Dementia Rating Scale, 31 and the Short Test of Mental Status. 32 Typically, subjects with aMCI perform above Ϫ1 SD below the appropriate means on non-memory measures. 23
Inclusion criteria and longitudinal characterization.
We studied 46 individuals who began the study as aMCI and progressed to a clinical diagnosis of AD. These subjects are labeled aMCI-P from here onward. For inclusion, aMCI-P cases must have had a minimum of three MRI scans with a diagnostic sequence of aMCI, AD, and AD. That is, they progressed from aMCI to AD and had at least one more AD scan after the diagnosis of AD. The first scan with a diagnosis of AD is referred to as the index scan and the date of this scan is referred to as the index date. One or more pre-and one or more post-index scans must have occurred within 3 years of the index scan.
A group of 46 subjects with CN were age-and gendermatched one to one to the aMCI-P subjects using the aMCI-P subjects' index date as the reference date for matching. In order to create a stable CN cohort with comparable inclusion criteria, we required that the timing of available scans match that used in assembling the aMCI-P cohort. That is, to be eligible for inclusion in the study, subjects with CN had to have three or more MRI scans each with a primary diagnosis of CN, and both the pre-and the postreference scans must have occurred within 3 years of the reference scan used for age and gender matching to subjects with aMCI-P. In addition, subjects with CN must have had no history of progression to a more impaired cognitive state for the entire available clinical longitudinal follow-up after the series of MRI studies. The decision to not right censor subjects with CN after the available series of MRI studies had ended but in whom additional clinical follow-up was available insured that we assembled a group for reference purposes that was as normal as possible. Short of autopsy, the best way to obtain a group of elderly normal subjects that is least likely to have subclinical pathology is to follow them as long as possible and exclude any who show significant cognitive decline. This approach has particular advantages in a study like this where the mean ages are near 80 and the probability of preclinical AD pathology is high. To the extent possible, when matching subjects we also tried to minimize the calendar time between the two subjects' index dates. This was done to minimize any potential variation due to MRI hardware/software upgrades between matched pairs of subjects in the two different clinical groups.
We also analyzed subjects with aMCI who remained clinically stable (i.e., did not convert to AD). These subjects are labeled aMCI-S from here onward. To be eligible for inclusion in the study, subjects with aMCI-S had to have three or more MRI scans each with a diagnosis of aMCI and no history of progression to dementia for the entire available longitudinal clinical follow-up after the series of MRI studies. As with the other two clinical groups, both the pre-and the post-reference scans must have occurred within 3 years of the reference scan. These criteria produced 23 available aMCI-S subjects in our database.
Any potential subject was excluded from the study if they had secondary clinical diagnoses that could potentially interfere with the volumetric measurements process or that introduced ambiguity about the subject's clinical progression. For example, subjects on dialysis or with unstable congestive heart failure were excluded. Figure 1 is a flow diagram illus-trating the derivation of the study samples of subjects with aMCI-P and aMCI-S from the source population. MRI methods. All MRI studies were performed with a standardized imaging protocol. T1-weighted threedimensional coronal volumetric SPGR images were used for all brain and ventricular volume measures with 124 contiguous partitions, and 1.6 mm slice thickness, 22 ϫ 16.5 cm field of view, minimum full echo time (TE), repetition time (TR) of 23 msec, and 25°flip angle. The presence of cerebrovascular disease was assessed on fluid attenuated inversion recovery (FLAIR) scans acquired with the following parameters: TR ϭ 11,000 msec; TE ϭ 147 msec; inversion time ϭ 2,250 msec; 3 mm interleaved images of the whole head. 33, 34 Total intracranial volume (TIV) was measured from sagittal T1spin echo images acquired with TR ϭ 500 msec and TE ϭ 14 msec. Different scanners were used, but all were GE Signa 1.5 T with body resonance module gradients and transmitreceive single channel head coils. All scanners undergo a standardized quality control calibration procedure every morning which monitors geometric fidelity over a 200 mm volume along all three cardinal axes, signal to noise ratio, and transmit gain.
Image processing steps were performed by a research technician (M.M.S.) who was blinded to all clinical information. Total intracranial volume (TIV) was measured by manually tracing the margin of the inner table of the skull on sagittal T1-weighted spin echo scans as described previously. 35, 36 Whole brain and ventricular atrophy rates were measured with the boundary shift integral (BSI) technique. 15, 37 Differences were calculated in pairwise fashion between the baseline scan and each subsequent scan in the temporal series. Following spatial and intensity normalization of the nth scan in the series to the baseline scan, intensity differences between the two scans at the brain-CSF boundary are used to compute change in volume. The whole brain atrophy rate reflects shrinkage of the brain on scan n relative to the baseline scan from out to in at the cortical surface and from in to out at the ventricular surface. The ventricular atrophy rate was derived by creating a binary mask for each subject that selectively extracted ventricular change. The binary mask was an approximate area overlaying the ventricles within which the BSI was measured. Quality control testing in our laboratory shows the nonparametric intraclass correlation coefficient for test-retest reproducibility of rate measurements from serial MRI scans with the boundary shift integral method is 0.91 for ventricle and 0.89 for brain. 13 The presence of cerebrovascular disease was assessed semiquantitatively on FLAIR scans by an experienced research technician (M.M.S.) who had no knowledge of the clinical information on cognitive status, gender, or age of the participant. The grading method was developed using a synthesis of published criteria. [38] [39] [40] [41] [42] Scans were graded in two categories. The number of lacunar infarcts was counted in each subject. White matter hyperintensity (WMH) load was graded with a visual analog scale. Each incoming FLAIR study was compared against a bank of example scans to assign it a WMH load in units of cm 3 . A bank of 10 example scans had been assembled from our database with increasing levels of WMH severity burden. WMH burden in units of cm 3 had been determined quantitatively for each example case using an algorithm developed in our laboratory. 43 The bank of example FLAIR studies was registered and resa-mpled in the space of a common template. Each new incoming FLAIR to be graded was likewise registered to the same common template. Therefore all scans were oriented in the same common template space for visual comparisons. The technician assigned each new incoming scan a WMH burden on a continuous scale (i.e., visual analog scale) relative to the bank of reference scans using an electronic slider bar. Quality control testing in our laboratory shows the intraclass correlation coefficient for inter-rater reliability of this visual analog WMH grading scale to be 0.96. The concordance correlation coefficient between quantitative measures and visual WMH grading is 0.93. The scans were viewed on a calibrated video monitor and entered into an electronic form linked to a database.
Statistical methods.
We performed two types of analyses using linear mixed-effects models to estimate the longitudinal change in ventricular and brain volumes. 44 The first analysis was among subjects with aMCI-P only and assessed whether there was an atrophy rate increase or decrease after the subjects progressed to a clinical diagnosis of AD. The second analysis was among all three groups and estimated the change in volume as a function of age.
For the first analysis, we fit a piecewise-linear mixed effects model with the time component expressed as years from the index scan. The model specified a random intercept and included fixed effects for TIV, sex, age at index scan, pre-index slope, and post-index slope. The fixed effects part of the model specified that volume change was linear before and after the index scan but allowed for a change in slope at the time of the index scan. The difference between pre-index and post-index slopes represents the estimated rate change after progression to AD. We evaluated whether rates before or after the index scan depended on age by including age by pre-index slope and age by post-index interactions and tested whether these terms were both zero.
For the second analysis, we fit a model with a random intercept and the following fixed effects: TIV, sex, group, age, age 2 , group by age interaction, and the group by age 2 interaction. Due to the interactions, this model allows for separate linear and quadratic age effects by group. We performed a four-degree of freedom "global" test of group differences to evaluate whether there was a common age and age 2 effect across groups. For each group, we also evaluated whether volume depended on age using a two-degree of free- dom test of whether the age and age 2 terms were zero.
Within group, we also tested the quadratic terms separately and whether volume changed with age after omitting the quadratic.
For comparison purposes, we examined cognitive decline over time by performing parallel analyses using the abovedescribed mixed-effects model methods applied to three tests: AVLT summed learning over trials 1 to 5, CDR sum of boxes (omitting CN subjects), and MMSE. Sex and education were included as fixed effects for all cognitive models while age at index scan was also included as a fixed effect when modeling change before and after the index scan.
To examine the effect of apolipoprotein E (APOE) 4 carrier status on volumes over time, we performed a similar agebased analysis among the combined aMCI groups (i.e., aMCI-P and aMCI-S). The model included a random intercept and fixed effects for TIV, sex, age, age 2 , and the interactions between APOE 4 carrier (yes vs no) and both age and age 2 .
For all mixed-model analyses we used restricted maximum likelihood estimation and modeled the within-subject correlation structure assuming Gaussian decay, such that two volume measures on the same subject x years apart would have a correlation of exp[Ϫ(x/a) 2 ] where a is estimated from the data. This implies for large interscan durations the within-subject correlation is small while as the interscan duration approaches zero, the within-subject correlation approaches 1.00. In sensitivity analyses, the choice of within-subject correlation structure had little impact on estimates of the rate of volume change. In our modeling we included covariates such as TIV and sex based on their biologic importance and interest and did not remove terms from the models based on significance level. Data handling and analysis was performed with SAS version 9.1.3 45 and R version 2.4.1 46 with the mixed effects models fit using the nlme package in R. 47 Further details on the mixed model specifications are presented in e-Materials on the Neurology ® Web site at www.neurology.org.
RESULTS
Forty-six subjects with aMCI-P, 23 subjects with aMCI-S, and 46 matched CN are included in this analysis (table 1). Volume measurements were derived from a total of 522 unique MRI scans with a median of five scans per subject with aMCI-P, three per subject with aMCI-S, and four per CN subject. The three groups did not differ on gender, age, or education (table 1). The proportion of APOE 4 carriers did not differ between the aMCI-P and aMCI-S groups (p ϭ 0.17), while CN had a lower proportion than either aMCI-P (p Ͻ 0.001) or aMCI-S (p ϭ 0.008). At the time of the index/reference MRI scan, performance on MMSE and CDR sum of boxes (SOB) was worse in aMCI-P than in aMCI-S subjects (both p Ͻ 0.001). Thirty-seven of the 46 subjects with aMCI-P (80%) and 7 of the 23 subjects with aMCI-S (30%) were being treated with cholinesterase inhibitors during the period in which scans were acquired. Neither the prevalence of central gray lacunar infarctions (p ϭ 0.57) nor the estimated white matter hyper intensity load (p ϭ 0.78) differed among the three clinical groups.
The demographic information above is in reference to the time of the index/match MRI scan date. However, in order to more fully characterize the criteria used to establish a clinical diagnosis of aMCI subjects in this study, table 2 lists baseline cognitive data used to make the diagnosis of aMCI at the time the first MRI scan was obtained. At this baseline point in time, performance on AVLT summed learning over trials 1 to 5, CDR SOB, and WMS logical memory II, paragraph recall was better in aMCI-S than aMCI-P subjects. Performance on MMSE, Wechsler Adult Intelligence Scale-Revised (WAIS-R) block design, and WAIS-R picture completion was not significantly different between the groups.
In order to assess the representativeness of the subjects with aMCI included in these analyses we Amnestic mild cognitive impairment progressors: ventricular and whole brain atrophy before and after Alzheimer disease diagnosis (index) scan
Thin gray lines represent a random sample of 23 individual subject volumes over time, thick black line indicates average volume. Average volumes are shown assuming a woman with a total intracranial volume of 1.4 L whose index scan is at age 79. compared demographic and cognitive characteristics of three groups of subjects: 1) the 344 subjects with aMCI with at least one MRI study in the ADPR/ADRC database who were not included in the study; 2) the 67 subjects with aMCI with serial MRI who were eligible on the basis of having serial MRI but were excluded from the analysis because they later progressed to non amnestic diagnoses, had medical exclusions, or had MRI artifacts that precluded analysis of the MRI data; and 3) the 69 subjects who were included in the analyses. The following data are listed by group in table e-1; % men/women, age, educational attainment, % APOE 4 carrier, summed learning over AVLT trials 1 to 5, CDR-SOB, MMSE, WMS logical memory II paragraph recall, WAIS-R block design, and WAIS-R picture completion. These values were calculated in each subject at the time of the earliest MRI scan on record coupled with a clinical diagnosis of aMCI. There were no differences among the three groups on any of the preceding variables except % APOE 4 carriers, which was greater (p ϭ 0.02) in the 69 subjects included in the analyses than the 67 excluded; the median WMS logical memory II, paragraph recall, which was lower by one point on average (p ϭ 0.048) in subjects with aMCI included in the analyses vs subjects without a qualifying number of scans; and WAIS-R block design, which was greater by one point on average (p ϭ 0.04) in subjects with aMCI in the analyses vs subjects without a qualifying number of scans.
Rates of ventricular expansion and brain shrinkage in subjects with aMCI-P from the piecewise-linear mixed effects model centered on index date are reported in units of cm 3 /year in table 3 and illustrated in figure 2 . Ventricular rates are reported as positive values reflecting increase in volume over time while brain rates are reported as negative values reflecting loss of volume over time. The 95% CI for both brain and ventricular rates before and after the index date did not include 0, indicating the presence of volume loss with time both before and after progression to AD. Rates of change after the index date were greater than before the index date for both ventricle and brain (both p Ͻ 0.001), indicating acceleration in atrophy rate as subjects progressed from aMCI to a clinical diagnosis of AD. The mean change in pre to post index date rate (i.e., acceleration) of ventricular atrophy was 1.7 cm 3 /year, and of brain was 5.3 cm 3 /year.
Using the same piecewise-linear mixed effects methods centered on index date, we estimated change with time of summed learning over trials 1 to 5 from the AVLT, CDR-SOB, and MMSE among subjects with aMCI-P ( figure 3 ). We used this learning measure from the AVLT rather than a measure of delayed recall because of floor effects on the recall measure (i.e., a number of subjects with aMCI-P had 0 recall in the latter stages of the testing series). There was no significant evidence for nonlinearity-i.e., no significant change in the rate of decline pre to post index date in the AVLT, but rates of declining performance did accelerate for both the CDR-SOB (p Ͻ 0.001) and MMSE (p Ͻ 0.001). Results of the piecewiselinear mixed effects modeling for AVLT, CDR-SOB, and MMSE for subjects with aMCI-P are reported in table e-2.
Results of the mixed model repeated measures analysis of volume by age for all three clinical groups are displayed in figure 4 for the ventricle and in figure 5 for brain. Volume change with age differed by group for the ventricle and brain (p Ͻ 0.001 for each). We report within-group tests of quadratic and linear age terms in table 4. In figures 4 and 5, the rate of ventricular expansion and brain shrinkage seems to slow with advancing age (i.e., atrophy rates are less in older subjects) in both subjects with aMCI-S and subjects with aMCI-P. Deceleration in atrophy rates was highly significant in subjects with aMCI-P with a trend in subjects with aMCI-S (table 4 ). In contrast, among CN subjects we did not detect a change with age in the rates of brain shrinkage and ventricular expansion-i.e., rates remained constant (figures 4 and 5, and table 4). Age-based mixed model coefficients are reported in tables e-3 and e-4 for ventricular and brain volume.
Results of the mixed model repeated measures analysis of cognitive test performance by age for all three clinical groups are displayed graphically for AVLT summed learning over trials 1 to 5, CDR-SOB, and MMSE. On the AVLT (figure 6), CN subjects' performance improved slightly from baseline and then remained flat; aMCI-S subjects' performance was flat from 70 to 80 years and then declined slightly; subjects with aMCI-P's performance declined starting at baseline. On the CDR-SOB (figure 7) CN subjects' performance was flat as expected; subjects with aMCI-S's performance declined minimally; and subjects with aMCI-P's performance declined dramatically starting at baseline. On the MMSE (figure 8) CN subjects' performance remained flat; subjects with aMCI-S's performance appears to have improved minimally; and subjects with aMCI-P's performance declined dramatically starting at baseline. There was evidence of accelerating declines in MMSE among subjects with aMCI-P (p ϭ 0.006) but no evidence of accelerating declines on the other two measures. Age-based mixed model coefficients are reported in tables e-5 through e-7 for AVLT, CDR-SOB, and MMSE.
The effect of APOE 4 carrier status on ventricular and brain rates by age was assessed in subjects with aMCI (aMCI-P and aMCI-S combined). These data are displayed in figure 9 . Volume change with age depended on APOE genotype in ventricle (p ϭ 0.005) and brain (p ϭ 0.015) with rates of both brain shrinkage and ventricular expansion overall greater in aMCI APOE 4 carriers than noncarriers. Among APOE 4 carriers we observed significant deceleration in rates with increasing age in ventricular volume (p Ͻ 0.001) and brain (p Ͻ 0.001). Among noncarri-
Figure 5
Change in brain volume with age by group ers, we observed deceleration for the brain (p ϭ 0.013) but not the ventricle (p ϭ 0.19) DISCUSSION Due to its progressive nature, a comprehensive picture of AD is best obtained through longitudinal observation. The rate at which various features of the disease progress with time is a topic of considerable research interest. Progression to a diagnosis of AD is a meaningful clinical event shared by all aMCI-P subjects in this study. Therefore, analyzing brain and ventricular volumes relative to this index point is a logical way to anchor the series of serial MRI studies in subjects with aMCI-P to a common clinically definable point in the natural history of the disease. A major objective of our study was to ascertain if rates of brain shrinkage and ventricular expansion change as individuals progressed from aMCI to a clinical diagnosis of AD. We found that both brain and ventricular rates accelerate during this portion of the disease course. This observation fits with some clinical observations of acceleration in the rate of cognitive decline in AD as the disease progresses. [48] [49] [50] As noted, 20 the anatomic substrate of acceleration in atrophy rates could be due to true acceleration in already affected areas, involvement of new areas, or both. To our knowledge, previous studies examining rate acceleration with three or more serial scans per subject have evaluated subjects with early onset AD, most of whom had known pathogenic mutations. 20, 21 One study 20 evaluated rates of brain loss with the boundary shift integral in 12 patients and another 21 from the same center modeled rates of brain and hippocampal atrophy in 9 patients. Both hippocampal and brain atrophy rates accelerated relative to index points defined using either a fixed MMSE score or a diagnosis of dementia. 20, 21 While the mean ages of subjects in these studies (47 years and 43 years) 20,21 were substantially younger than our subjects with aMCI-P (79 years), the finding of acceleration in rates as subjects progressed to dementia was similar. However, linear rate estimates in terms of percentage brain volume lost per year are considerably higher in familiar young onset cases-on the order of 2% to 3% of brain volume lost per year. 20 In contrast, annualized rates of atrophy in elderly subjects with aMCI-P from our center are 0.8% per year. 12, 13 Comparing the data in young familial onset disease 20, 21 with our data in late onset cases leads to the conclusion that the qualitative nature of the disease in the window of time where subjects progress to dementia is similar regardless of age at onset. However, the quantitative nature of disease (i.e., absolute linear rates) is more aggressive in younger onset disease.
As with MRI data, rates of decline in CDR-SOB and MMSE performance accelerated as subjects with aMCI progressed to AD, while rates of decline on AVLT summed learning did not accelerate significantly. In addition, if one compares the individual trajectories in cognitive performance vs time relative to index scan in figure 3 with MRI volumes in figure 2, it appears as though there is greater random variation in the cognitive measures compared to the MRI measures, particularly for the AVLT, although we did not explicitly compare stability of the downward trend in MRI vs cognitive tests.
Analysis of volume vs time relative to the index point at which subjects with aMCI progress to a diagnosis of AD is sensible in subjects with aMCI-P; however, there is no similar common clinical event with which to anchor CN subjects or subjects with aMCI-S in time. Hence in a sec- ond analysis we estimated change in brain and ventricular volume as a function of age in all three clinical groups. Among all three clinical groups, aMCI-P, aMCI-S, and CN, ventricular volume increased and brain volume decreased with advancing age (figures 4 and 5; table 4 ). This result was expected and is consistent with earlier longitudinal and cross sectional imaging studies. However, the rate of ventricular expansion and brain shrinkage slowed with advancing age-i.e., atrophy rates were less in older subjects with aMCI-P with a similar trend in subjects with aMCI-S. This presents an apparent paradox. From the volume vs index date modeling we conclude that rates of atrophy accelerate with time as individual subjects progress from aMCI to AD. From the volume vs age modeling we conclude that rates of atrophy are less in older than younger subjects with aMCI-P. One possible explanation is that this is the result of selection bias, as these subjects were not drawn randomly from an epidemiologically defined sample. However, we note that de-mographic and cognitive performance differences between subjects with aMCI analyzed in this study and the larger pool of all subjects with aMCI with at least one MRI study in the ADPR/ ADRC data base were minimal. Another way to resolve this apparent paradox is to propose that our younger subjects with aMCI-P on average had a more biologically aggressive disease course than our older subjects with aMCI-P. This is consistent with observations of some clinicians that younger onset subjects have a more aggressive clinical course. As noted in the paragraph above, if we compare rates of percentage brain volume lost per year in our 79-year-old subjects with aMCI-P to subjects with young onset familial AD, 20, 21 we find faster rates in the younger subjects with AD. The trend toward slower rates in older subjects with aMCI-S in our study could be attributed to the same phenomenon; i.e., more aggressive disease in younger onset subjects. This assumption implies that at least a proportion of subjects with aMCI who did not progress were actually progressing and at some point a proportion of the aMCI-S group will progress to AD. Further longitudinal follow-up is necessary to confirm this. It is important to note that in labeling subjects with aMCI-S, we do not imply that these subjects will not develop AD in their lifetimes; rather that they did not over the entire observation period currently available in each. Mixed model repeated measures analysis of cognitive test performance by age was qualitatively similar for AVLT summed learning, CDR-SOB, and MMSE. CN and aMCI-S subjects' performance remained relatively flat while aMCI-P subjects' performance displayed a noticeable decline starting at baseline. It is interesting that while the rate of brain and ventricular atrophy slows in older subjects with aMCI-P, no slowing with age is seen in either AVLT or CDR-SOB and the rate of decline in MMSE accelerates slightly. We note that in contrast to the volumetric measurements, subjects' cognitive performance was used to assign clinical diagnosis. Therefore, it is not surprising that the longitudinal pattern on cognitive tests differs markedly between subjects with aMCI-S and aMCI-P.
The number of CN subjects in our study is too small to draw sweeping conclusions about normal aging. However, among CN subjects the rates of brain shrinkage and ventricular expansion did not change with age (as indicated by the linear volume change over time). The relationship between brain size and age in nondemented individuals has been addressed through cross sec- tional studies of individuals spanning various age ranges. Many cross-sectional studies of aging find decreasing volumes of brain, ventricle, or specific regions of interest with advancing age. 41, [51] [52] [53] [54] The effect of age on brain size has also been addressed in studies which employ pairs of scans, from which linear rates are measured, acquired in individuals spanning various age ranges. [55] [56] [57] [58] Some of these studies indicate a linear decline in brain, ventricle, or regional volume with age in nondemented subjects while others indicate acceleration with advancing age, often at an inflection point in middle or older age. Interaction of rates of atrophy with risk factors, such as hypertension, has also been described. 55 There is no evidence that differences in rates among groups in our study are due to differences in prevalence of lacunar infarcts or white matter hyper intensity load.
A strength of this study was the fact that we were able to acquire serial MRI data using consistent methods for a period extending over a decade. This same feature, however, also imposes a potential limitation. Over 10 years, multiple software upgrades are unavoidable. The scanners used in this study were no exception. Fortunately, both the gradient hardware and transmit-receive head coils used on the scanners in this study were unchanged throughout the duration of the data collection. In addition, a rigorous daily quality control procedure was in place throughout the study. This consisted of a standardized daily calibration procedure which monitors geometric fidelity over a 200 mm volume along all three cardinal axes, signal to noise ratio, and transmit gain. Nonetheless, we acknowledge the inevitable noise which must have been introduced into our data given the long time period over which the MRI studies were obtained.
The proportion of APOE 4 carriers was greatest in our subjects with aMCI-P and least in CN subjects as would be expected. This is consistent with the well established fact that AOPE 4 increases the risk of developing AD. 59 Had we examined rates of atrophy as a function of APOE 4 carrier status across all clinical groups combined, the results would have been a forgone conclusion since both the proportion of APOE 4 carriers and atrophy rates were highest among aMCI-P and lowest among CN. We therefore analyzed the effect of APOE 4 carrier status within the subjects with aMCI (aMCI-P and aMCI-S) combined. The rationale for this is that at the beginning of any longitudinal study, the eventual clinical outcome (progressor vs stable) of individual subjects with aMCI is unknown. Findings in our study on the relationship between MRI rates and APOE 4 status are relevant to planning of future studies (both therapeutic and observational) that employ brain volumes as an outcome measure. Some implications are that studies should be powered based on an anticipated APOE 4 effect on atrophy rates; therapeutic studies using MRI as an outcome measure could be designed to balance APOE 4 status across treatment groups; and a nonlinear effect of APOE 4 on brain rates might be anticipated. Our finding of higher rates of atrophy in APOE 4 carriers is consistent with some literature. 60 However, the literature itself is not consistent. Some reports indicate that APOE 4 increases risk of AD but not the rate of clinical progression. [61] [62] [63] [64] [65] In fact, some publications indicate that the rate of clinical progression is slower in APOE 4 carriers than noncarriers. 66, 67 Brain atrophy measures from serial MRI studies have most commonly been treated as a linear function in past studies; i.e., a line is fit to scans acquired at two time points. However, our data indicate that while the deviation from linearity is relatively minor, rates of both brain shrinkage and ventricular expansion accelerate in individual subjects with aMCI who progress to AD. Using a linear estimate for a nonlinear function will tend to be invalid when comparing rates of change across subjects who have different interscan intervals, different intrinsic rates of change, or both. Our data indicate that such errors should be fairly minor in studies of elderly subjects with aMCI when the interscan interval is limited to a year or so. In future studies, however, it might be useful to incorporate nonlinearity in models of longitudinal morphometric change, especially when modeling change over periods exceeding 1 to 2 years. AD is a disease which evolves over decades. Conclusions drawn from our analyses are relevant only to the relatively narrow window in the overall progression of the disease that we examined. Our conclusions about rates and change in rate with time should not be extrapolated outside the range that we examined in the overall course of the disease.
